Subject: rosuvastatin
Subject: vascular endothelial growth factor
Subject: epidermal growth factor
Subject: cardiovascular risk
Year: 2021
Type: Article
Title: Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk
Author: Ana Vavlukis
Author: Marija Vavlukis
Author: Aleksandar Dimovski
Author: Gordana Petrushevska
Author: Aleksandar Eftimov
Author: Sashka Domazetovska
Author: Kristina Mladenovska
Abstract: Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data were collected from patients’ records, physical examination, and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein (p = 0.045), and increased vascular endothelial growth factor (p = 0.004) and epidermal growth factor (p = 0.009). A multivariate analysis identified total cholesterol (p = 0.027) and vascular endothelial growth factor (p = 0.011) to be independently associated with rosuvastatin treatment. Given the beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.
Publisher: Walter de Gruyter GmbH
Relation: Acta Pharmaceutica
Identifier: oai:repository.ukim.mk:20.500.12188/16374
Identifier: VAVLUKIS A, VAVLUKIS M, DIMOVSKI A, PETRUSHEVSKA G, EFTIMOV A, DOMAZETOVSKA S, MLADENOVSKA K. Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk. Acta Pharmaceutica.;72(2):303-15.
Identifier: http://hdl.handle.net/20.500.12188/16374Identifier: 10.2478/acph-2022-0018
Identifier: https://www.sciendo.com/pdf/10.2478/acph-2022-0018Identifier: 72
Identifier: 2
